Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission
- 12 January 2023
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (6) , 2789-2797
Abstract
Biologic treatment withdrawal in inflammatory bowel disease patients with prolonged remission may lead to benefits but also increases the risk of getting a relapse. The risk of relapse after biologic withdrawal according to the Dutch STOP-criteria is still unknown. The aim of this study was to compare the cumulative incidence of relapse in inflammatory bowel disease patients that discontinued biologic therapy after applying the STOP-criteria with patients who maintained biologic therapy. We performed a mono-centre, observational, retrospective study by evaluating relapse risk of patients treated with biologic agents who discontinued this treatment according to the STOP-criteria (STOP-group) compared to patients who were in remission for more than 3 years before withdrawal (LATERSTOP-group) and patients who continued their biologic (MAINTAIN-group). The cumulative risk was calculated at 12 and 36 months using the log-rank test to compare Kaplan–Meier curves. Eighty-three of 398 patients that used biologics between 1 January 2010 and 1 January 2020 were included. The cumulative relapse incidences in the STOP-group and the LATERSTOP-group were, respectively, 29% and 42% at 12 months and 47% versus 58% at 36 months. Patients in the MAINTAIN-group showed a lower (p = 0.03) cumulative relapse incidence of 10% at 12 months and 18% at 36 months. Patients who discontinued their biologic therapy according to the STOP-criteria had significantly more relapses at 12 and 36 months than patients who maintained biologic treatment.Keywords
This publication has 31 references indexed in Scilit:
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's DiseaseGastroenterology, 2014
- Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapyAlimentary Pharmacology & Therapeutics, 2012
- Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center studyScandinavian Journal of Gastroenterology, 2012
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is StoppedGastroenterology, 2012
- Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohortAlimentary Pharmacology & Therapeutics, 2010
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Safety of anti-tumor necrosis factor therapy in inflammatory bowel diseaseWorld Journal of Gastroenterology, 2009
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative ColitisInflammatory Bowel Diseases, 2008
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?Alimentary Pharmacology & Therapeutics, 2005